Telix Pharmaceuticals Limited - American Depositary Shares (TLX) closed at $8.92 on November 16, 2026, down 3.4% from the previous close, on volume of 216,435 shares (30-day average 327,521).
Data as of November 16, 2026.
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Telix Reports Third Quarter 2026 Financial Performance
Globe Newswire (Tue, 20-Oct 6:10 PM ET)
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Globe Newswire (Mon, 19-Oct 1:30 AM ET)
Globe Newswire (Fri, 9-Oct 7:45 AM ET)
Globe Newswire (Tue, 6-Oct 6:30 AM ET)
Market Chameleon (Mon, 21-Sep 7:09 AM ET)
Market Chameleon (Mon, 21-Sep 3:32 AM ET)
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Globe Newswire (Sun, 20-Sep 8:55 PM ET)
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
Globe Newswire (Mon, 14-Sep 6:30 AM ET)
Globe Newswire (Wed, 9-Sep 6:30 AM ET)
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Telix Pharmaceuticals Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol TLX.
As of November 16, 2026, TLX stock price declined to $8.92 with 216,435 million shares trading.
TLX has a beta of 1.08, meaning it tends to be more sensitive to market movements. TLX has a correlation of 0.06 to the broad based SPY ETF.
TLX has a market cap of $3.03 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that TLX belongs to (by Net Assets): APIE.
TLX has underperformed the market in the last year with a return of -6.2%, while the SPY ETF gained +11.2%. In the last 3 month period, TLX fell short of the market, returning -27.7%, while SPY returned -4.6%. However, in the most recent 2 weeks TLX has outperformed the stock market by returning -2.0%, while SPY returned -2.1%.
TLX support price is $8.99 and resistance is $9.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLX shares will trade within this expected range on the day.